◎ Sugi Atlas

Atlas / Drug / Ginkgo

Ginkgo

drug
On this page

Also known as B1260Common ginkgo leafCommon ginkgo wholeEGB 761EGB-761Ginkgo bilobaGinkgo biloba extractGinkgo biloba leafGinkgo biloba leaf dry extractGinkgo biloba leaf extractGinkgo biloba leaf powderGinkgo biloba leaf tinctureGinkgo biloba wholeext.Ginkgo foliumGinkgo folium (ginkgo biloba l.)Ginkgo leafGinkgo leaf (ginkgo biloba l.)Ginkgo macrophylla leaf

Summary

Ginkgo (CHEMBL2108466) is an approved unknown (ATC N06DX02); indicated across 17 conditions including dementia and vestibular neuronitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • ATC class: N06DX02
  • Indications: 17 conditions
  • Clinical trials: 39

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108466
NameGinkgo
TypeUnknown
Max phase4
ATCN06DX02

Also known as: B1260, Common ginkgo leaf, Common ginkgo whole, EGB 761, EGB-761, Ginkgo, Ginkgo biloba, Ginkgo biloba extract, Ginkgo biloba leaf, Ginkgo biloba leaf dry extract, Ginkgo biloba leaf extract, Ginkgo biloba leaf powder

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

17 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
dementia4MONDO:0001627HP:0000726
vestibular neuronitis3MONDO:0006008EFO:0007537
sleep disorder3MONDO:0100081EFO:0008568
open-angle glaucoma2MONDO:0005338EFO:0004190
physiological sexual disorder2MONDO:0002134EFO:0004714
Alzheimer disease2MONDO:0004975MONDO:0004975
Parkinson disease2MONDO:0005180MONDO:0005180
Friedreich ataxia2MONDO:0100339MONDO:0100339
vitiligo1MONDO:0008661EFO:0004208
skin disorder1MONDO:0005093EFO:0000701
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
multiple sclerosis1MONDO:0005301MONDO:0005301
retinitis pigmentosa0MONDO:0019200MONDO:0019200

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 39.

Phase distribution

PhaseTrials
Not specified11
PHASE210
PHASE46
PHASE35
PHASE1/PHASE23
PHASE12
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06495476PHASE4NOT_YET_RECRUITINGStudy on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
NCT07579689PHASE4NOT_YET_RECRUITINGEffects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment
NCT00042172PHASE4COMPLETEDTreatment for Early Memory Loss
NCT01046292PHASE4COMPLETEDEffect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI
NCT02982603PHASE4COMPLETEDEfficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment
NCT04846179PHASE4COMPLETEDTo Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
NCT00010803PHASE3COMPLETEDGinkgo Biloba Prevention Trial in Older Individuals
NCT00010920PHASE3COMPLETEDPreventing Cognitive Decline With Alternative Therapies
NCT00046891PHASE3COMPLETEDEGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
NCT01637168PHASE3WITHDRAWNComparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders
NCT02098330PHASE3COMPLETEDThe Efficacy of Steroid Therapy in Vestibular Neuritis
NCT06403787PHASE2/PHASE3COMPLETEDEffect of Aerobic Training and Ginkgo Biloba on Lipids Levels in HIV-positive Patients Undergoing Antiretroviral Treatment
NCT04525144PHASE2RECRUITINGEGb 761 in the Syndrome of MCI With Concomitant CVD
NCT06813274PHASE2NOT_YET_RECRUITINGMulticenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling
NCT07287852PHASE2ENROLLING_BY_INVITATIONA Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
NCT00010842PHASE1/PHASE2COMPLETEDNatural Antioxidants in the Treatment of Multiple Sclerosis
NCT00029692PHASE2COMPLETEDEffects of Ginseng and Ginkgo on Drug Disposition in Man
NCT00032474PHASE1/PHASE2COMPLETEDGinkgo Biloba Extract and the Insulin Resistance Syndrome
NCT00034021PHASE2COMPLETEDGinkgo Biloba: Antidepressant-Induced Sexual Dysfunction
NCT00070954PHASE1/PHASE2TERMINATEDGinkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)
NCT00841321PHASE2COMPLETEDTrial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
NCT01139281PHASE2COMPLETEDThe Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01416818PHASE2UNKNOWNTreatment of Depression in Parkinson’s Disease
NCT02376114PHASE2COMPLETEDGinkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma
NCT02425436PHASE2COMPLETEDRole of Ginkgo Biloba Extract in IUGR
NCT00011063PHASE1COMPLETEDEffect of Ginkgo Biloba on Phenytoin Elimination
NCT00907062PHASE1COMPLETEDGinkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents
NCT02386852EARLY_PHASE1COMPLETEDGinseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity
NCT06140888Not specifiedNOT_YET_RECRUITINGEffect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke
NCT01524380Not specifiedCOMPLETEDGinkgo Biloba Extract for Schizophrenia
NCT01663467Not specifiedWITHDRAWNEfficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy
NCT03125551Not specifiedWITHDRAWNROTEM and Dietary Supplements
NCT03216681Not specifiedCOMPLETEDHoat Huyet Nhat Nhat Versus Tanakan for Treatment of Symptoms Related to the Insufficient Blood Supply to the Brain
NCT03425045Not specifiedCOMPLETEDRepetitive Transcranial Magnetic Stimulation for Chronic Subjective Tinnitus
NCT03475823Not specifiedCOMPLETEDCognitive and Blood Flow Effects of Mountain Tea
NCT04121728Not specifiedUNKNOWNModulation of Attention in Event Related Potential (ERPs) as a Marker of Early Cognitive Decline by Ginkgo Biloba
NCT05258123Not specifiedCOMPLETEDGinkgo Biloba Extract in the Treatment of Schizophrenia
NCT05591144Not specifiedCOMPLETEDShort-term Oral Prednisone for Acute Subjective Tinnitus
NCT06124703Not specifiedUNKNOWNDifferent Dosing Regimens of STOP-AST

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 14

This page pulls from 14 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem